Polymers as Drugs

In vitro chelating, cytotoxicity, and blood compatibility of degradable poly(ethylene glycol)-based macromolecular iron chelators

“…Once the payload has been delivered, it is essential that the polymer is then cleared from circulation [21]. In contrast, there are few examples of polymer-drug conjugates (macromolecular therapeutics) whereby the drug remains with the polymer support while the therapeutic dose is being delivered [24][25][26]. One such example involved the conjugation of DFO to a dextran or starch polymer [15,27,28].…”

“…DFO was conjugated to a PEG-containing copolymer in order to develop a highly blood compatible and long circulating macromolecular chelator which can bind iron in the body and be excreted through the kidney [35]. The presence of PEG and a resulting increase in the Stokes radius of the bound DFO might improve vascular retention, making it more suitable for systemic vascular applications [25]. DFO is conjugated to the polymer support through stable amide linkages, while PEG chains are conjugated via degradable ester bonds.…”

Bazı Maleik Anhidrit İçeren Kopolimerlerin Amin Yapılı İlaç Etken Maddeleri İle Türevlendirilmesi, Yapısal Karakterizasyonu ve Biyolojik Aktiviteleri

“…Bu kopolimer antikoagulan ve antienflamatuvar ajan olarak kullanıldığı gibi antiviral, antibakteriyel ve antifungal etkinliğe de sahiptir (9,10). Ticari olarak pazarlanan en popüler kopolimer ise SMA olarak da bilinen poli(stiren-komaleik asit/anhidrit)'tir (2,11).…”

Chitosan: A Desirable Candidate for Treating Hyperphosphatemia?

“…The binding capacity is based on the ionic hydrogen bond between phosphate anions and amines spaced on the polymer backbone ( Fig. 1) [35]. But the key contraindications for sevelamer administration are a history of intestinal obstruction, followed by swallowing disorders [36].…”